Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.
Acromegaly is caused by excessive growth hormone secretion, usually from a pituitary adenoma. Increased mortality rate is reverted to that of the normal population after decreasing GH and IGF-I levels to less than 2-2.5 microg/liter and normal sex- and age-matched controls, respectively, regardless of the treatment employed. The use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. A few cases have been reported in the literature, complete shrinkage of a pituitary GH secreting macroadenoma after long-term somatostatin analogue administration. We report a patient in whom long term (60 months) octreotide-L.A.R administration resulted in complete disappearance of a growth hormone secreting pituitary macroadenoma.
Ozbek
M
M
Ankara Dişkapi Education and Research Hospital, Endocrinology and Metabolism Disease, Ankara, Turkey.
Erdogan
M
M
Akbal
E
E
Gönülalan
G
G
D000236:Adenoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D011859:Radiography; D012074:Remission Induction; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors
D003692:Delayed-Action Preparations; D013004:Somatostatin; D015282:Octreotide